Plasma insulin profiles after subcutaneous injection: How close can we get to physiology in people with diabetes?

Diabetes, Obesity and Metabolism

Volumn 17, Issue 11, 2015, Pages 1011-1020

  Home, P D ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Analogue; Basal; Diabetes; Insulin therapy; Meal; Physiology

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN PEGLISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; RECOMBINANT HUMAN INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ANTIDIABETIC ACTIVITY; CONTINUOUS INFUSION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG RELEASE; FEEDBACK SYSTEM; FEEDING BEHAVIOR; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOINSULINEMIA; INFUSION PUMP; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN RELEASE; INSULIN SENSITIVITY; INSULIN SYNTHESIS; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PLASMA CLEARANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; STOMACH ABSORPTION; TISSUE ENGINEERING; WEIGHT GAIN; BLOOD; DIABETES MELLITUS; DRUG EFFECTS; MEAL; PATHOPHYSIOLOGY; PHYSIOLOGY; POSTPRANDIAL STATE; SUBCUTANEOUS DRUG ADMINISTRATION;

BLOOD GLUCOSE; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; MEALS; POSTPRANDIAL PERIOD;

EID: 84944581052     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12501     Document Type: Review

References (93)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
3. Moore MC, Smith MS, Turney MK, Boysen S, Williams PE. Comparison of insulins detemir and glargine: effects on glucose disposal, hepatic glucose release and the central nervous system. Diabetes Obes Metab 2011; 13: 832-840.
4. Homko C, Deluzio A, Jimenez C, Kolaczynski JW, Boden G. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. Diabetes Care 2003; 26: 2027-2031.
5. Meneghini LF. Insulin therapy for type 2 diabetes. Endocrine 2013; 43: 529-534.
6. Grunberger G. The need for better insulin therapy. Diabetes Obes Metab 2013; 15(Suppl. 1): 1-5.
7. Riddle MC, Rosenstock J, Gerich J, Insulin Glargine Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
8. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009; 169: 1307-1316.
9. Ganz ML, Wintfeld NS, Li Q, Lee YC, Gatt E, Huang JC. Severe hypoglycemia rates and associated costs among type 2 diabetics starting basal insulin therapy in the United States. Curr Med Res Opin 2014; 30: 1991-2000.
10. Hartman I. Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res 2008; 6: 54-67.
11. National Institute for Health and Care Excellence (NICE). Diagnosis and management of type 1 diabetes in children, young people and adults. NICE clinical guideline 15. 2004 (last modified July 2014). 2004 Available from URL: https://www.nice.org.uk/guidance/cg15/resources/guidance-type-1-diabetes-pdf. Accessed 8 April 2015.
12. Saad A, Dalla Man C, Nandy DK et al. Diurnal pattern to insulin secretion and insulin action in healthy individuals. Diabetes 2012; 61: 2691-2700.
13. Lucidi P, Rossetti P, Porcellati F et al. Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysis. Diabetes 2010; 59: 1349-1357.
14. Bourey RE, Koranyi L, James DE, Mueckler M, Permutt MA. Effects of altered glucose homeostasis on glucose transporter expression in skeletal muscle of the rat. J Clin Invest 1990; 86: 542-547.
15. Pørksen N, Juhl C, Hollingdal M et al. Concordant induction of rapid in vivo pulsatile insulin secretion by recurrent punctuated glucose infusions. Am J Physiol Endocrinol Metab 2000; 278: E162-170.
16. Pørksen N. The in vivo regulation of pulsatile insulin secretion. Diabetologia 2002; 45: 3-20.
17. Wahren J, Felig P, Ahlborg G, Jorfeldt L. Glucose metabolism during leg exercise in man. J Clin Invest 1971; 50: 2715-2725.
18. Hovorka R, Kumareswaran K, Harris J et al. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ 2011; 342: d1855.
19. Sun L, Zhang X, Zheng C, Wu Z, Li C. A pH gated, glucose-sensitive nanoparticle based on worm-like mesoporous silica for controlled insulin release. J Phys Chem B 2013; 117: 3852-3860.
20. Pagliuca FW, Millman JR, Gurtler M et al. Generation of functional human pancreatic beta cells in vitro. Cell 2014; 159: 428-439.
21. Rosenstock J, Bergenstal RM, Blevins TC et al. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. Diabetes Care 2013; 36: 522-528.
22. Jacober SJ, Rosenstock J, Bergenstal RM, Prince MJ, Qu Y, Beals JM. Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM. Diabetes Obes Metab 2014; 16: 351-356.
23. Kruszynska YT, Home PD, Hanning I, Alberti KG. Basal and 24-h C-peptide and insulin secretion rate in normal man. Diabetologia 1987; 30: 16-21.
24. Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obes Metab 2012; 14: 780-788.
25. Koivisto VA, Yki-Jarvinen H, Helve E, Karonen SL, Pelkonen R. Pathogenesis and prevention of the dawn phenomenon in diabetic patients treated with CSII. Diabetes 1986; 35: 78-82.
26. Birkeland KI, Home PD, Wendisch U et al. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011; 34: 661-665.
27. Heller S, Buse J, Fisher M et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1489-1497.
28. Francis AJ, Home PD, Hanning I, Alberti KG, Tunbridge WM. Intermediate acting insulin given at bedtime: effect on blood glucose concentrations before and after breakfast. Br Med J (Clin Res Ed) 1983; 286: 1173-1176.
29. Gale EA, Kurtz AB, Tattersall RB. In search of the Somogyi effect. Lancet 1980; 2: 279-282.
30. Mitrakou A, Kelley D, Veneman T et al. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 1990; 39: 1381-1390.
31. Kemmer F. Chapter 35. Exercise. In: Alberti K, DeFronzo R, Keen H, Zimmet P, eds. International Textbook of Diabetes Mellitus. 2nd edn. Chicester: John Wiley 1997, 799-815.
32. Dagogo-Jack SE, Craft S, Cryer PE. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest 1993; 91: 819-828.
33. Ashwell SG, Amiel SA, Bilous RW et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabet Med 2006; 23: 285-292.
34. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008; 51: 408-416.
35. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002; 25: 593-598.
36. Caumo A, Luzi L. First-phase insulin secretion: does it exist in real life? Considerations on shape and function. Am J Physiol Endocrinol Metab 2004; 287: E371-385.
37. Nauck MA, Homberger E, Siegel EG et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492-498.
38. Diakogiannaki E, Gribble FM, Reimann F. Nutrient detection by incretin hormone secreting cells. Physiol Behav 2012; 106: 387-393.
39. Rhodes CJ, Halban PA. Newly synthesized proinsulin/insulin and stored insulin are released from pancreatic B cells predominantly via a regulated, rather than a constitutive, pathway. J Cell Biol 1987; 105: 145-153.
40. Riccardi G, Rivellese AA. Effects of dietary fiber and carbohydrate on glucose and lipoprotein metabolism in diabetic patients. Diabetes Care 1991; 14: 1115-1125.
41. Zimmet PZ, Wall JR, Rome R, Stimmler L, Jarrett RJ. Diurnal variation in glucose tolerance: associated changes in plasma insulin, growth hormone, and non-esterified fatty acids. Br Med J 1974; 1: 485-488.
42. Oram RA, Jones AG, Besser RE et al. The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia 2014; 57: 187-191.
43. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014; 37(Suppl. 1): S81-90.
44. Davis AK, DuBose SN, Haller MJ et al. Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care 2015; 38: 476-481.
45. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003; 46: 3-19.
46. Gerich JE. Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes? Diabetes 2002; 51(Suppl. 1): S117-121.
47. Kahn SE, Carr DB, Faulenbach MV, Utzschneider KM. An examination of beta-cell function measures and their potential use for estimating beta-cell mass. Diabetes Obes Metab 2008; 10(Suppl. 4): 63-76.
48. Brunzell JD, Robertson RP, Lerner RL et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976; 42: 222-229.
49. 1c. Diabetes Care 2003; 26: 881-885.
50. Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care 2011; 34: 2508-2514.
51. Holman RR, Turner RC. Optimizing blood glucose control in type 2 diabetes: an approach based on fasting blood glucose measurements. Diabet Med 1988; 5: 582-588.
52. Polonsky KS, Given BD, Hirsch LJ et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988; 318: 1231-1239.
53. Elahi D. In praise of the hyperglycemic clamp. A method for assessment of beta-cell sensitivity and insulin resistance. Diabetes Care 1996; 19: 278-286.
54. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992; 41: 368-377.
55. Lefebvre PJ, Luyckx AS, Lecomte MJ. Studies on the pathogenesis of reactive hypoglycemia: role of insulin and glucagon. Horm Metab Res 1976; Suppl 6: 91-98.
56. Rayner CK, Samsom M, Jones KL, Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 2001; 24: 371-381.
57. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care 1984; 7: 188-199.
58. Sindelka G, Heinemann L, Berger M, Frenck W, Chantelau E. Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia 1994; 37: 377-380.
59. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23: 644-649.
60. Lepore M, Pampanelli S, Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148.
61. Home PD, Hanning I, Capaldo B, Alberti KG. Bioavailability of highly purified bovine ultralente insulin. Diabetes Care 1983; 6: 210.
62. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004; 47: 622-629.
63. Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med 2006; 23: 879-886.
64. Kurtzhals P. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int J Obes Relat Metab Disord 2004; 28(Suppl. 2): S23-28.
65. -1. Diabetes Care 2014; 38: 637-643.
66. ®, in subjects with type 1 diabetes mellitus (T1DM) (Abstract 891-P). Diabetes 2014; 63(Suppl. 1): A228.
67. European Medicines Agency. Guideline on non-clinical and clinical development of 4 similar biological medicinal products containing 5 recombinant human insulin and insulin analogues. 2014. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/04/WC500165988.pdf. Accessed 8 April 2015.
68. Pedersen-Bjergaard U, Kristensen PL, Beck-Nielsen H et al. Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial. Lancet Diabetes Endocrinol 2014; 2: 553-561.
69. Frier BM, Russell-Jones D, Heise T. A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review. Diabetes Obes Metab 2013; 15: 978-986.
70. Swinnen SG, Simon AC, Holleman F, Hoekstra JB, Devries JH. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011: CD006383.
71. ® Basal-Bolus Type 1): 2-year results of a randomized clinical trial. Diabet Med 2013; 30: 1293-1297.
72. Riddle MC, Bolli GB, Ziemen M, Muehlen-Bartmer I, Bizet F, Home PD. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care 2014; 37: 2755-2762.
73. Zinman B, Philis-Tsimikas A, Cariou B et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012; 35: 2464-2471.
74. Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012; 14: 944-950.
75. Mathieu C, Hollander P, Miranda-Palma B et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 2013; 98: 1154-1162.
76. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012; 29: 2104-2114.
77. Yki-Jarvinen H, Bergenstal R, Ziemen M et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care 2014; 37: 3235-3243.
78. Bolli GB, Riddle MC, Bergenstal RM et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab 2015; 17: 386-394.
79. Home PD, Bergenstal RM, Bolli GB et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care 2015; 38; DOI: 10.2337/dc2315-0249 [Epub ahead of print].
80. Bergenstal RM, Bailey TS, Rodbard D et al. Insulin glargine 300 U/ml vs 100 U/ml: glucose profiles of morning vs evening injections in adults with type 1 diabetes mellitus measured with continuous glucose monitoring (CGM) (Abstract 949). Diabetologia 2014; 57(Suppl. 1): S388.
81. Sinha VP, Choi SL, Soon DK et al. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. J Clin Pharmacol 2014; 54: 792-799.
82. Sinha VP, Howey DC, Choi SL, Mace KF, Heise T. Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2014; 16: 344-350.
83. Bergenstal RM, Rosenstock J, Arakaki RF et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012; 35: 2140-2147.
84. Colquitt J, Royle P, Waugh N. Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabet Med 2003; 20: 863-866.
85. Rebrin K, Sheppard NF Jr, Steil GM. Use of subcutaneous interstitial fluid glucose to estimate blood glucose: revisiting delay and sensor offset. J Diabetes Sci Technol 2010; 4: 1087-1098.
86. US Food and Drug Administration. FDA news release: FDA approves Afrezza to treat diabetes. 2014. Available from URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm403122.htm. Accessed 8 April 2015.
87. Zisser H, Jovanovic L, Markova K et al. Technosphere insulin effectively controls postprandial glycemia in patients with type 2 diabetes mellitus. Diabetes Technol Ther 2012; 14: 997-1001.
88. US Food and Drug Administration. Summary minutes of the Endocrinologic and Metabolic Drugs Advisory Committee Meeting. April 1, 2014. 2014. Available from URL: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm386727.htm. Accessed 8 April 2015.
89. Morrow L, Muchmore DB, Hompesch M, Ludington EA, Vaughn DE. Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase. Diabetes Care 2013; 36: 273-275.
90. Krasner A, Brazg RL, Blevins TC et al. Safety and efficacy of ultra-rapid-acting human insulin formulation BIOD-123 in patients with type 1 diabetes (Abstract 130-OR). Diabetes 2014; 63(Suppl. 1): A34.
91. Morrow L, Krasner A, Canney L, Hompesch M, Pichotta P, Souza ED. Biphasic pharmacokinetic and pharmacodynamic profiles associated with concentrated insulin BIOD-531 show rapid onset and basal duration of action (Abstract 937). Diabetologia 2014; 57(Suppl. 1): S383.
92. Heise T, Hövelmann U, Brøndsted L, Adrian CL, Nosek L, Haahr H. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab 2015; 17: 682-688.
93. ® in people with type 1 and type 2 diabetes. 2015. Available from URL: http://www.novonordisk.com/bin/getPDF.1906174.pdf. Accessed 8 April 2015.